$RARE News

Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade)

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46

Ultragenyx Nabs FDA Nod for First Gene Therapy

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript

Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $103

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Obtains FDA Accelerated Approval For GENGLYCOS In Adult And Pediatric Patients Eight Years And Older With Glycogen Storage Disease Type Ia

RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy

Ultragenyx: Undervalued Ahead Of Two FDA Decisions

Ultragenyx (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclusive License For Generic DOJOLVI From 2033

HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $50 Price Target

Is Q2 Revenue Growth And Narrower Loss Altering The Investment Case For Ultragenyx Pharmaceutical (RARE)?

Has Ultragenyx Pharmaceutical (RARE) Fallen Far Enough To Avoid Overvaluation?

Ultragenyx Pharmaceutical (RARE) Following Q2 Results Looks Close To Fair Value

Ultragenyx Pharmaceutical Inc. Q2 2026 Earnings Call Summary

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45